Amphibian peptide RL-QN15 accelerates vaginal mucosal repair by modulating inflammation, autophagy, and apoptosis
Background
Vaginal mucosal injury, stemming from factors like infection, trauma, or estrogen deficiency, presents a significant clinical challenge with limited effective therapeutic options. Current treatments often fall short in addressing the complex interplay of cellular processes crucial for repair. Autophagy and apoptosis are critical regulators of mucosal regeneration, yet how therapeutic peptides can precisely modulate these pathways to promote healing remains largely unexplored. This gap highlights the need for novel, multi-targeted agents that can effectively restore mucosal integrity and function.
Study Design
Researchers investigated the therapeutic potential of RL-QN15 in both in vitro and in vivo models of LPS-induced inflammatory injury. In vitro, rat vaginal epithelial cells were treated with RL-QN15 to assess proliferation via CCK-8 and EdU assays, IL-6 secretion by ELISA, and apoptosis using TUNEL and Annexin V-FITC/PI flow cytometry. Expression of autophagy and apoptosis markers (LC3-II/I, Beclin1, p62, Bax, Bcl-2, cleaved caspase-3) was analyzed by Western blot. In vivo, LPS-injured rat vaginal mucosa was treated with RL-QN15, with outcomes evaluated by mucosal thickness, IL-6 levels, and tissue-level autophagy/apoptosis marker analysis via Western blot, comparing efficacy against erythromycin ointment.
Results
RL-QN15 significantly reversed LPS-induced suppression of proliferation and autophagy, while inhibiting apoptosis and IL-6 expression in vitro. In vivo, RL-QN15 demonstrated superior efficacy, reducing mucosal thickness and enhancing epithelial integrity. Notably, RL-QN15 suppressed IL-6 levels, outperforming erythromycin ointment via direct statistical comparison. Mechanistically, RL-QN15 restored autophagic flux, evidenced by modulated LC3-II/I, Beclin1, and p62 levels, and rebalanced apoptosis by influencing Bax/Bcl-2 ratios and caspase-3 activity in both cellular and tissue models. This multi-pronged action underscores its regenerative capacity.
RL-QN15 significantly reversed LPS-induced suppression of proliferation and autophagy, while inhibiting apoptosis and IL-6 expression in vitro, and outperformed erythromycin ointment in vivo.
Key Findings
- RL-QN15 significantly reversed LPS-induced suppression of proliferation and autophagy in vitro.
- RL-QN15 inhibited apoptosis and
IL-6expression in rat vaginal epithelial cells. - In vivo, RL-QN15 reduced mucosal thickness and enhanced epithelial integrity in LPS-injured rat vaginas.
- RL-QN15 suppressed
IL-6levels in vivo, outperforming erythromycin ointment. - Mechanistically, RL-QN15 restored autophagic flux and rebalanced apoptosis pathways.
Why It Matters
This study identifies RL-QN15 as a promising multitarget peptide therapeutic for vaginal mucosal injury, offering a novel approach beyond current limited options. Its ability to simultaneously modulate inflammation, autophagy, and apoptosis suggests a comprehensive healing mechanism, potentially leading to more robust and sustained repair. For peptide users and clinicians, this opens avenues for exploring new regenerative strategies, particularly in conditions where infection or trauma compromise mucosal integrity. While currently a preclinical finding, the direct comparison and superior performance against an established treatment like erythromycin ointment highlight its translational potential, though a usable protocol for humans is still distant, requiring extensive clinical development.
rl-qn15
vaginal-mucosa
mucosal-repair
inflammation
autophagy
apoptosis